Omicia delivers a market-leading software platform that enables analysis, interpretation, and reporting on genomic data to expedite diagnosis and improve medical outcomes. Omicia's products are in use at more than 500 world-class academic and clinical institutions worldwide. By accelerating understanding of the genetic basis of disease, drug response, and health, Omicia is unlocking the potential of individualized medicine.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/09/16 | $23,000,000 | Series B |
Acadia Woods Partners Artis Ventures Buchanan Investments LDV Partners Ping An Ventures Roche Venture Fund UPMC Enterprises | undisclosed |
